Page last updated: 2024-12-07

fim 1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fim 1: fluorescein-conjugated bis(indole)maleimide inhibitor of protein kinase C; can serve as useful fluorescent probe for protein kinase C [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132906
MeSH IDM0219425

Synonyms (6)

Synonym
150206-03-4
spiro(isobenzofuran-1(3h),9'-(9h)xanthene)-5-carboxamide, 3',6'-bis(acetyloxy)-n-(3-(3-(2,5-dihydro-4-(1-methyl-1h-indol-3-yl)-2,5-dioxo-1h-pyrrol-3-yl)-1h-indol-1-yl)propyl)-3-oxo-
fim 1
[6'-acetyloxy-5-[3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propylcarbamoyl]-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl] acetate
DTXSID60164495
AKOS025394539
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (57.14)18.2507
2000's3 (42.86)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.99 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index41.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]